-
Arrowhead Pharmaceuticals NASDAQ:ARWR Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead's RNAi-based therapeutics leverage this natural pathway of gene silencing.
Location: 177 E Colorado Blvd, Suite 700, California, 91105, US | Website: arrowheadpharma.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
2.368B
Cash
434.5M
Avg Qtr Burn
-87.89M
Short % of Float
8.20%
Insider Ownership
4.47%
Institutional Own.
80.49%
Qtr Updated
06/30/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Plozasiran (ARO-APOC3) Details Familial chylomicronemia syndrome | NDA Submission | |
Plozasiran (ARO-APOC3) Details Severe hypertriglyceridemia | Phase 3 Data readout | |
Fazirsiran (ARO-AAT) (TAK-999) Details Severe alpha-1 antitrypsin deficiency, Liver disease | Phase 3 Update | |
Plozasiran (ARO-APOC3) Details Dyslipidemia | Phase 3 Initiation | |
Zodasiran (ARO-ANG3) Details Dyslipidemia | Phase 2b Update | |
ARO-ANG3 Details Dyslipidemia | Phase 2 Update | |
ARO-CFB Details Complement mediated diseases, Kidney disease, IgA nephropathy | Phase 1/2 Data readout | |
ARO-DM1 Details Myotonic Dystrophy Type 1 | Phase 1/2 Data readout | |
ARO-MMP7 Details Idiopathic pulmonary fibrosis | Phase 1/2 Data readout | |
ARO-MUC5AC Details Lung disease, Muco-Obstructive Lung Diseases | Phase 1/2 Data readout | |
ARO-C3 (RNAi) Details Renal disease, Paroxysmal nocturnal hemoglobinuria | Phase 1/2 Data readout | |
ARO-RAGE Details Muco-Obstructive Lung Diseases, Inflammatory disease, Asthma | Phase 1/2 Update | |
ARO-INHBE Details Obesity, Metabolic disorder | Phase 1/2 Initiation | |
ARO-DUX4 Details Facioscapulohumeral muscular dystrophy | Phase 1/2 Initiation | |
JNJ-3989 (ARO-HBV) Details Hepatitis B | Failed Discontinued | |
ARO-HSD Details Liver disease, Non-alcoholic steatohepatitis | Failed Discontinued |